RDNT:NSD-RadNet Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 67.11

Change

+0.30 (+0.45)%

Market Cap

USD 5.01B

Volume

0.81M

Analyst Target

USD 21.67
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

-0.97 (-0.19%)

USD 41.20B
ICLR ICON PLC

+9.91 (+3.39%)

USD 24.84B
ILMN Illumina Inc

+0.76 (+0.58%)

USD 20.58B
NTRA Natera Inc

-0.11 (-0.09%)

USD 15.65B
EXAS EXACT Sciences Corporation

+1.22 (+1.79%)

USD 11.40B
MEDP Medpace Holdings Inc

+6.64 (+1.87%)

USD 10.90B
SHC Sotera Health Co

+0.08 (+0.48%)

USD 4.76B
NEOG Neogen Corporation

+0.37 (+2.19%)

USD 3.50B
GH Guardant Health Inc

-0.01 (-0.04%)

USD 3.30B
TWST Twist Bioscience Corp

-0.65 (-1.36%)

USD 2.75B

ETFs Containing RDNT

PSCH Invesco S&P SmallCap Heal.. 3.28 % 0.29 %

+0.10 (+0%)

USD 0.20B
WMCR 0.00 % 0.50 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 93.01% 92% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 93.01% 92% A 94% A
Trailing 12 Months  
Capital Gain 139.17% 92% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 139.17% 92% A 96% N/A
Trailing 5 Years  
Capital Gain 348.00% 100% F 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 348.00% 100% F 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 40.46% 78% C+ 88% B+
Dividend Return 40.46% 78% C+ 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 56.55% 52% F 32% F
Risk Adjusted Return 71.54% 96% N/A 88% B+
Market Capitalization 5.01B 86% B+ 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector